http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10161940-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec0024795f45a646ef64b3664ab8a26d http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56ae261117a45b117334efe3d1a51a66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e8f93a1343a400a745b221c18d9af30 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y101-01042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-904 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001154 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-43 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00 |
filingDate | 2013-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2018-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9f79b4bc5050896229cf4d398694985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cd00b446fb363397016568dc9c49449 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e34ba3c9fbfc69260d0e7ce7314b466a |
publicationDate | 2018-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-10161940-B2 |
titleOfInvention | Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers |
abstract | The present invention concerns the field of tumor therapeutics and diagnostics. Specifically, it relates to a peptide comprising at least 8 amino acids in length which are present as contiguous amino acid sequence in the human Isocitratdehydrogenase Type 1 (IDH1), wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132, for use in preventing and/or treating cancer. Further contemplated is a medicament comprising the said peptide. Furthermore, the invention relates to a method for diagnosing cancer characterized by having a mutation in the genome of at least some cancer cells which results in the expression of a mutant IDH1 having the R132H mutation comprising the steps of contacting a blood sample of a subject suspected to suffer from such a cancer with a peptide comprising at least 10 amino acids in length which are present as contiguous amino acid sequence in the IDH1, wherein said peptide has at least one amino acid exchange from R to H at a position corresponding to position 132 for a time and under conditions which allow for specific binding of a component of the immune system to the peptide, and determining whether, or not, binding of the said component of the immune system to the peptide occurred, wherein the cancer is diagnosed if the occurrence of binding has been determined. Provided by the invention is also a kit and a device for carrying out said method. |
priorityDate | 2012-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 252.